CN105611942A - 针对艰难梭菌免疫的组合物和方法 - Google Patents

针对艰难梭菌免疫的组合物和方法 Download PDF

Info

Publication number
CN105611942A
CN105611942A CN201480044768.7A CN201480044768A CN105611942A CN 105611942 A CN105611942 A CN 105611942A CN 201480044768 A CN201480044768 A CN 201480044768A CN 105611942 A CN105611942 A CN 105611942A
Authority
CN
China
Prior art keywords
days
day
toxin
subjects
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480044768.7A
Other languages
English (en)
Chinese (zh)
Inventor
P.皮特罗邦
G.福利亚
G.德布鲁因
S.古鲁纳桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105611942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN105611942A publication Critical patent/CN105611942A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480044768.7A 2013-06-14 2014-06-13 针对艰难梭菌免疫的组合物和方法 Pending CN105611942A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
US61/835246 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
CN105611942A true CN105611942A (zh) 2016-05-25

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480044768.7A Pending CN105611942A (zh) 2013-06-14 2014-06-13 针对艰难梭菌免疫的组合物和方法

Country Status (12)

Country Link
US (4) US9730994B2 (https=)
EP (1) EP3007724B1 (https=)
JP (1) JP6691477B2 (https=)
KR (1) KR20160020543A (https=)
CN (1) CN105611942A (https=)
AU (1) AU2014277981B2 (https=)
BR (1) BR112015031088A2 (https=)
CA (1) CA2915279A1 (https=)
MX (1) MX2015017257A (https=)
SG (1) SG11201510166YA (https=)
TW (1) TWI648063B (https=)
WO (1) WO2014201346A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111629750A (zh) * 2017-09-28 2020-09-04 辉瑞公司 用于引发针对艰难梭菌的免疫应答的组合物和方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
CN101855336A (zh) * 2007-09-14 2010-10-06 赛诺菲巴斯德生物制剂公司 含艰难梭菌类毒素a和b的药物组合物
CN105308066A (zh) * 2013-03-15 2016-02-03 圣诺菲·帕斯图尔公司 类毒素、组合物和相关的方法
CN105338997A (zh) * 2013-03-15 2016-02-17 圣诺菲·帕斯图尔公司 类毒素、组合物和相关的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
CN101855336A (zh) * 2007-09-14 2010-10-06 赛诺菲巴斯德生物制剂公司 含艰难梭菌类毒素a和b的药物组合物
CN105308066A (zh) * 2013-03-15 2016-02-03 圣诺菲·帕斯图尔公司 类毒素、组合物和相关的方法
CN105338997A (zh) * 2013-03-15 2016-02-17 圣诺菲·帕斯图尔公司 类毒素、组合物和相关的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
傅思武: "艰难梭菌B毒素的纯化及其生物学特性", 《中国生物制品学杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111629750A (zh) * 2017-09-28 2020-09-04 辉瑞公司 用于引发针对艰难梭菌的免疫应答的组合物和方法
CN111629750B (zh) * 2017-09-28 2024-06-11 辉瑞公司 用于引发针对艰难梭菌的免疫应答的组合物和方法

Also Published As

Publication number Publication date
JP2016521754A (ja) 2016-07-25
SG11201510166YA (en) 2016-01-28
US20210145956A1 (en) 2021-05-20
AU2014277981A1 (en) 2016-01-07
JP6691477B2 (ja) 2020-04-28
CA2915279A1 (en) 2014-12-18
US9730994B2 (en) 2017-08-15
US20170304423A1 (en) 2017-10-26
US11419930B2 (en) 2022-08-23
KR20160020543A (ko) 2016-02-23
TW201536314A (zh) 2015-10-01
TWI648063B (zh) 2019-01-21
EP3007724B1 (en) 2023-07-05
AU2014277981B2 (en) 2019-06-20
US20200113991A1 (en) 2020-04-16
MX2015017257A (es) 2016-11-11
US20160120968A1 (en) 2016-05-05
EP3007724A1 (en) 2016-04-20
WO2014201346A1 (en) 2014-12-18
BR112015031088A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
US11419930B2 (en) Compositions and methods for immunizing against C. difficile
TWI308872B (en) Improved mycoplasma hyopneumoniae bacterin vaccine
KR20180054629A (ko) 장외 병원성 e. 콜리에 대한 면역 보호를 위한 방법 및 조성물
RU2723045C2 (ru) Композиции neisseria meningitidis и способы их получения
US20250312432A1 (en) Compositions and methods for eliciting an immune response against clostridium difficile
RU2559782C2 (ru) Набор для детекции спор, происходящих из микобактерий
RU2442603C2 (ru) Вакцина против вируса синего языка и иммуногенные композиции, способы их применения и способы их получения
TW202438104A (zh) 誘發針對困難梭狀芽孢桿菌之免疫反應的免疫原性組成物和方法
Camussone et al. Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant
JP2023113631A (ja) クロストリジウム類毒素を含むワクチン
Jarosova et al. Effects of oil-based adjuvants on the immune response of pigs after dermal administration of antigen and evaluation of the immunization level after a subsequent Actinobacillus pleuropneumoniae challenge in pigs
WO2019092027A1 (en) Sapelovirus immunogenic compositions and uses thereof
JP7399865B2 (ja) 哺乳動物における趾皮膚炎に使用されるワクチン組成物
US20210220459A1 (en) Vaccine compositions
CN110507819A (zh) 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
WO2019081583A1 (en) VACCINE AGAINST SINGLE STEM DYSENTERY
CA3082608C (en) Vaccine compositions for use against digital dermatitis in a mammal
Won et al. Development of a bacterin–toxoid vaccine using a Korean isolate for protection against caseous lymphadenitis in goats
US20220313816A1 (en) Compositions and methods for antibody-as-adjuvant vaccines and therapeutics
KR20230091978A (ko) 면역원성 항원
RU2570630C2 (ru) Способ снижения серопозитивности живых противобруцеллезных вакцин для сельскохозяйственных животных
Mohammad Pour-dounighi et al. Humoral immune response to Diphtheria and Tetanus toxoids by intranasal administration
Pour-Dounighi et al. Humoral immune response to Diphtheria and Tetanus toxoids by intranasal administration.
Ozpolat Development of a protective vaccine against Helicobacter pylori

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160525